4BIO Capital
Venture Capital
Active
London, United States
20
42M
15
2.00
3
0.25
5
- Stages of investment
- Areas of investment
Summary
In 2014 was created 4BIO Capital, which is appeared as VC. The fund was located in Europe if to be more exact in United Kingdom. The main office of represented VC is situated in the London.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the 4BIO Capital, startups are often financed by Woodford Investment Management, Syncona Partners LLP, ODYSSEE VENTURE. The meaningful sponsors for the fund in investment in the same round are UCL Technology Fund, Temasek Holdings, RTW Investments LLC. In the next rounds fund is usually obtained by Auven Therapeutics, AstraZeneca, Redmile Group.
The fund is generally included in less than 2 deals every year. The higher amount of exits for fund were in 2018. This 4BIO Capital works on 51 percentage points more the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2017.
The fund has exact preference in some founders of portfolio startups. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Orchard Therapeutics, Atara Biotherapeutics, Cellectis. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom.
This organization was formed by Andrey Kozlov, Dmitry Kuzmin. We also calculated 3 valuable employees in our database.
Investor highlights
- Industry focus
- Stage focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 20
- Lead investments
- 3
- Exits
- 5
- Rounds per year
- 2.00
- Follow on index
- 0.25
- Investments by industry
- Biotechnology (18)
- Life Science (6)
- Therapeutics (5)
- Health Care (5)
- Medical (4) Show 8 more
- Investments by region
-
- United States (7)
- United Kingdom (5)
- France (4)
- Switzerland (3)
- Japan (1)
- Peak activity year
- 2022
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Group Appearance index
- 0.75
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Hornet Therapeutics | 23 May 2024 | Seed | 5M | England, London, United Kingdom | |
| mytech | 06 Jun 2017 | E-Commerce, Retail, B2B | Early Stage Venture | 1M | Sichuan, Qingyang District, China |
| Ray Therapeutics | 04 Jan 2022 | Biotechnology, Therapeutics | Seed | 6M | United States, California, San Diego |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.